# Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion

**Authors:** Ilaria Trozzi, Beatrice Giorgi, Riccardo De Paola, Milo Gatti, Federico Pea

PMC · DOI: 10.3390/pharmaceutics18010091 · 2026-01-10

## TL;DR

The paper introduces two fast and accurate methods to monitor antibiotic levels in patients' blood, helping doctors adjust doses for better treatment outcomes.

## Contribution

The study develops and validates two UPLC–qTOF–MS/MS methods for simultaneous quantification of five novel beta-lactams and fosfomycin in plasma.

## Key findings

- The methods showed excellent linearity (R² ≥ 0.998) and quantification limits between 1.56 and 15.62 µg/mL.
- Precision and accuracy were within ±15%, with recovery rates exceeding 92%.
- The methods are robust and suitable for real-time therapeutic drug monitoring in critically ill patients.

## Abstract

Background/Objectives: Therapeutic drug monitoring (TDM) of β-lactams (BL), BL/β-lactamase inhibitor (BLI) combinations (BL/BLIc), and of fosfomycin may play a key role in optimizing antimicrobial therapy and in preventing resistance development, especially when used by continuous infusion in critically ill or immunocompromised patients. Unfortunately, analytical methods for simultaneously quantifying multiple BL/BLIc in plasma are still lacking. Methods: The aim of this study was to develop and validate two rapid, sensitive, and accurate UPLC–qTOF–MS/MS methods for the simultaneous quantification of five novel β-lactam or β-lactam/β-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, cefiderocol, and ceftobiprole) along with fosfomycin. Methods: Human plasma samples were prepared by protein precipitation using methanol containing isotopically labeled internal standards. Chromatographic separation was achieved within 10–12 min using two Agilent Poroshell columns (EC-C18 and PFP) under positive and negative electrospray ionization modes. The method was validated according to the EMA guidelines by assessing selectivity, linearity, precision, accuracy, matrix effects, extraction recovery, and stability. Results: The methods exhibited excellent linearity (R2 ≥ 0.998) across the calibration ranges for all of the analytes (1.56–500 µg/mL), with limits of quantification ranging from 1.56 to 15.62 µg/mL. Intra- and inter-day precision and accuracy were always within ±15%. Extraction recovery always exceeded 92%, and the matrix effects were effectively corrected through isotopic internal standards. No carry-over or isobaric interferences were observed. All the analytes were stable for up to five days at 4 °C, but the BL and BL/BLIc stability was affected by multiple freeze–thaw cycles. Conclusions: These UPLC-qTOF-MS/MS multi-analyte methods enabled a simultaneous, reliable quantification in plasma of five novel beta-lactams and of fosfomycin. Robustness, high throughput, and sensitivity make these multi-methods feasible for real-time TDM, supporting personalized antimicrobial dosing and improved therapeutic outcomes in patients with severe or multidrug-resistant infections.

## Linked entities

- **Chemicals:** ceftolozane/tazobactam (PubChem CID 86291594), ceftazidime/avibactam (PubChem CID 90643431), meropenem/vaborbactam (PubChem CID 86298703), cefiderocol (PubChem CID 77843966), ceftobiprole (PubChem CID 135413542), fosfomycin (PubChem CID 441029)

## Full-text entities

- **Diseases:** infections (MESH:D007239)
- **Chemicals:** meropenem (MESH:D000077731), ceftobiprole (MESH:C443755), cefiderocol (MESH:C000612166), ceftolozane/tazobactam (MESH:C000594038), Fosfomycin (MESH:D005578), methanol (MESH:D000432), vaborbactam (MESH:C000626994), ceftazidime/avibactam (MESH:C000595613), BL (MESH:D047090)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12845176/full.md

---
Source: https://tomesphere.com/paper/PMC12845176